0001415889-23-011447.txt : 20230724
0001415889-23-011447.hdr.sgml : 20230724
20230724194508
ACCESSION NUMBER: 0001415889-23-011447
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230721
FILED AS OF DATE: 20230724
DATE AS OF CHANGE: 20230724
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pontes Josias
CENTRAL INDEX KEY: 0001868415
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39746
FILM NUMBER: 231106164
MAIL ADDRESS:
STREET 1: C/O SIGILON THERAPEUTICS, INC.
STREET 2: 100 BINNEY STREET, SUITE 600
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sigilon Therapeutics, Inc.
CENTRAL INDEX KEY: 0001821323
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474005543
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 BINNEY STREET
STREET 2: STE 600
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-336-7540
MAIL ADDRESS:
STREET 1: 100 BINNEY STREET
STREET 2: STE 600
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
form4-07242023_110705.xml
X0508
4
2023-07-21
0001821323
Sigilon Therapeutics, Inc.
SGTX
0001868415
Pontes Josias
C/O SIGILON THERAPEUTICS, INC.
100 BINNEY STREET STE 600
CAMBRIDGE
MA
02142
false
true
false
false
CHIEF FINANCIAL OFFICER
0
Common Stock
2023-07-21
4
M
0
1444
19.24
A
3254
D
Stock Option (Right to Buy)
19.24
2023-07-21
4
M
0
1444
0
D
2032-02-17
Common Stock
1444
3171
D
Includes 786 shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") for the purchase periods from October 1, 2021 to March 31, 2023. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock. These transaction are exempt under Rule 16b-3(c).
Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split.
The option vested as to 25% of the underlying shares of common stock on February 18, 2023, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.
/s/ Matthew Kowalsky, Attorney-in-Fact
2023-07-24